The US Food and Drug Administration (USFDA) has granted final approval to Zydus Lifesciences to produce and sell Roflumilast Tablets, 250 mcg (USRLD: Daliresp Tablets, 250 mcg). Roflumilast lessens pulmonary inflammatory disease that causes chronic obstructive pulmonary disease (COPD). When someone has severe COPD, it is used to stop the symptoms from getting worse. The group’s formulation manufacturing facility in SEZ Ahmedabad will produce the medication (India).
Shopping Cart